Home/Filings/3/0000899243-22-025275
3//SEC Filing

HILZ MARK T 3

Accession 0000899243-22-025275

CIK 0001468492other

Filed

Jul 5, 8:00 PM ET

Accepted

Jul 6, 1:40 PM ET

Size

26.8 KB

Accession

0000899243-22-025275

Insider Transaction Report

Form 3
Period: 2022-06-14
HILZ MARK T
DirectorSee Remarks
Holdings
  • Warrants

    Exercise: $2.89From: 2021-11-17Exp: 2026-10-12Common Stock (30 underlying)
  • Warrants

    Exercise: $3.47From: 2013-08-23Exp: 2023-08-23Common Stock (644 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $12.21Exp: 2026-05-01Common Stock (18,939 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $15.18Exp: 2028-11-01Common Stock (7,576 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $1.29Exp: 2029-09-01Common Stock (22,727 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $1.29Exp: 2030-11-06Common Stock (26,515 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $12.21Exp: 2026-05-01Common Stock (3,788 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $15.18Exp: 2028-03-14Common Stock (7,576 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $3.47Exp: 2032-03-01Common Stock (26,515 underlying)
  • Warrants

    Exercise: $3.47From: 2013-06-28Exp: 2023-06-28Common Stock (379 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $15.18Exp: 2028-03-14Common Stock (7,576 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $15.18Exp: 2028-03-14Common Stock (7,576 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $1.29Exp: 2030-11-06Common Stock (26,515 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $3.47Exp: 2032-03-01Common Stock (26,515 underlying)
  • Common Stock

    441,522
  • Series C Convertible Preferred Stock

    Exercise: $6.59Common Stock (7,894 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $15.18Exp: 2028-11-01Common Stock (7,576 underlying)
  • Employee Stock Option (Right to Buy)

    Exercise: $15.18Exp: 2028-11-01Common Stock (7,576 underlying)
  • Common Stock

    (indirect: By Daughter)
    4,040
  • Employee Stock Option (Right to Buy)

    Exercise: $1.29Exp: 2029-09-01Common Stock (30,303 underlying)
Footnotes (15)
  • [F1]The Convertible Preferred Stock may be converted at any time, at the Holder's election and there is no expiration. The conversion ratio is 3.7954 shares of Common Stock for each share of Series C Preferred Stock.
  • [F10]The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F11]The entire option has become fully-vested and may be exercised at any time at the Holder's election.
  • [F12]The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F13]The option becomes fully-vested and may be exercised at any time at Holder's election upon the receipt of at least $15 million pursuant to the Company's sale of debt or equity securities or borrowings from any debt financing source. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F14]The entire option has become fully-vested and may be exercised at any time at the Holder's election.
  • [F15]The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F2]The entire option has become fully-vested and may be exercised at any time at the Holder's election.
  • [F3]The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F4]The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F5]The option becomes fully-vested and may be exercised at any time at Holder's election upon the Company having one calendar quarter of positive EBITDA. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F6]The option becomes fully-vested and may be exercised at any time at Holder's election upon the sale of a specified number of units of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F7]The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F8]The option becomes fully-vested and may be exercised at any time at Holder's election upon the Company having one calendar quarter of positive EBITDA. As of the date of this filing, the performance-based criteria have not been satisfied.
  • [F9]The option becomes fully-vested and may be exercised at any time at Holder's election upon the sale of a specified number of units of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.

Issuer

Heart Test Laboratories, Inc.

CIK 0001468492

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001016157

Filing Metadata

Form type
3
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 1:40 PM ET
Size
26.8 KB